

The Manager
Company Announcements Office
ASX Limited

LBT TO PRESENT AT MELBOURNE INVESTOR FORUM

Melbourne, 8 February 2017: LBT Innovations (LBT) will today present at the Twilight Investor Forum in Melbourne. LBT CEO and Managing Director, Brent Barnes is one of two CEOs presenting to about 60 investors and brokers.

The complete presentation is attached and key developments relevant to stakeholders are summarised below:

APAS® via Clever Culture Systems:

- APAS® Independence development on track to achieve first major milestone of a working demonstration device on display at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in April 2017;
- Continued high interest from potential distribution partners, however they value the importance of seeing a functional demonstration device;
- “Letter of Intent” with potential distribution partner(s) likely to be superseded. Expected timing of commercial distribution agreement(s) April-November 2017 following successful launch of demonstration device starting in April 2017.

MicroStreak® Sale or License:

- Deloitte appointed to lead global process;
- Target timing to finalise commercial outcome: Q3, 2017 (*calendar year*).

Financial:

- A two tranche placement to professional and sophisticated investors was completed in January 2017 that raised \$7m;
- Proceeds are being used to accelerate product development and commercialisation of APAS technology.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has two world class-leading products in microbiology automation: MicroStreak®, which provides automated culture plate streaking and Automated Plate Assessment System (APAS®). Based on LBT's intelligent imaging and interpretative software, US FDA-approved APAS® automates imaging, analysis and interpretation of culture plates following incubation. LBT has entered into a joint venture Clever Culture Systems AG (CCS) with Hettich AG Switzerland to commercialise APAS® products. LBT's third product WoundVue® is in early development; this is a proposed automated solution to assist in the management of chronic wounds.

For more information, see www.lbtinnovations.com

CONTACTS

LBT Innovations	Media Relations
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 (0)8 8227 1555 E: info@lbtinnovations.com	Rudi Michelson Monsoon Communications Tel: +61 (0)3 9620 3333 M: +61 (0) 411 402 737 E: rudim@monsoon.com.au